Platform-derived Therapeutics/Diagnostics
Broad-spectrum cancers (e.g., lung, colon, breast, hematological)
Clinical-stageActive
Key Facts
Indication
Broad-spectrum cancers (e.g., lung, colon, breast, hematological)
Phase
Clinical-stage
Status
Active
Company
About Multimmune
Multimmune is a German biotech pioneer in the theranostics space, built on a foundational discovery of membrane Hsp70 as a pan-cancer biomarker. The company's proprietary platform aims to develop both diagnostics and therapeutics targeting this marker, applicable across approximately 50-75% of cancers, including many solid tumors and hematological malignancies. As a private, clinical-stage entity, its strategy centers on creating a single, broad-spectrum approach to cancer treatment and imaging, positioning it within the precision medicine paradigm. The technology holds particular promise for targeting metastatic disease, which expresses even higher levels of the target.
View full company profile